$-0.02 EPS Expected for Pieris Pharmaceuticals, Inc. (PIRS); 8 Analysts Covering Orion Engineered Carbons, S.A. (OEC)

April 17, 2018 - By Kurt Siggers

Analysts expect Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) to report $-0.02 EPS on May, 9.They anticipate $0.17 EPS change or 89.47% from last quarter’s $-0.19 EPS. After having $0.17 EPS previously, Pieris Pharmaceuticals, Inc.’s analysts see -111.76% EPS growth. The stock increased 1.71% or $0.11 during the last trading session, reaching $6.54. About 146,393 shares traded. Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) has risen 146.76% since April 17, 2017 and is uptrending. It has outperformed by 135.21% the S&P500.

Among 11 analysts covering Orion Engineered Carbons (NYSE:OEC), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Orion Engineered Carbons had 26 analyst reports since August 10, 2015 according to SRatingsIntel. As per Friday, May 12, the company rating was initiated by Goldman Sachs. The firm has “Neutral” rating given on Monday, August 7 by JP Morgan. The rating was maintained by UBS on Friday, November 3 with “Neutral”. The company was maintained on Friday, February 23 by UBS. Goldman Sachs upgraded Orion Engineered Carbons, S.A. (NYSE:OEC) on Friday, July 14 to “Buy” rating. Northcoast maintained the stock with “Buy” rating in Monday, February 26 report. The rating was maintained by JP Morgan with “Overweight” on Tuesday, March 6. The company was upgraded on Monday, November 6 by J.P. Morgan. The firm earned “Equal-Weight” rating on Tuesday, November 7 by Barclays Capital. The stock of Orion Engineered Carbons, S.A. (NYSE:OEC) has “Neutral” rating given on Friday, October 30 by UBS. See Orion Engineered Carbons, S.A. (NYSE:OEC) latest ratings:

06/03/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $29 New Target: $30 Maintain
26/02/2018 Broker: Barclays Capital Rating: Hold New Target: $30.0
26/02/2018 Broker: Northcoast Rating: Buy New Target: $35.0 Maintain
26/02/2018 Broker: KeyBanc Capital Markets Old Rating: Buy New Rating: Buy Old Target: $29 New Target: $33 Maintain
23/02/2018 Broker: UBS Old Rating: Neutral New Rating: Neutral Old Target: $23 New Target: $29 Maintain
22/01/2018 Broker: Jefferies Rating: Buy New Target: $38.0 Initiate
16/01/2018 Broker: KeyBanc Capital Markets Rating: Buy New Target: $29.0 Maintain
07/11/2017 Broker: Barclays Capital Rating: Equal-Weight Old Target: $23 New Target: $25 Maintain
06/11/2017 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Old Target: $23 Upgrade
06/11/2017 Broker: J.P. Morgan Rating: Buy New Target: $29.0 Upgrade

Among 9 analysts covering Pieris Pharmaceuticals (NASDAQ:PIRS), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Pieris Pharmaceuticals had 19 analyst reports since July 22, 2015 according to SRatingsIntel. The stock of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) earned “Buy” rating by Oppenheimer on Thursday, August 17. The rating was maintained by JMP Securities with “Buy” on Monday, March 19. The company was initiated on Tuesday, July 28 by Oppenheimer. H.C. Wainwright maintained the shares of PIRS in report on Wednesday, December 20 with “Buy” rating. The firm earned “Buy” rating on Tuesday, February 13 by H.C. Wainwright. H.C. Wainwright maintained the stock with “Buy” rating in Friday, August 11 report. The stock has “Buy” rating by Roth Capital on Friday, August 5. The stock has “Buy” rating by H.C. Wainwright on Tuesday, May 30. On Wednesday, August 12 the stock rating was initiated by JMP Securities with “Market Outperform”. The stock of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) has “Buy” rating given on Wednesday, July 22 by TH Capital.

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin drugs. The company has market cap of $352.21 million. It develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. It currently has negative earnings. The firm primarily focuses on the development of four drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases; PRS-343, a bispecific protein for oncology diseases; and PRS-332, a bispecific anticalin-antibody fusion protein for oncology diseases.

The stock increased 0.96% or $0.275 during the last trading session, reaching $28.825. About 102,812 shares traded. Orion Engineered Carbons, S.A. (NYSE:OEC) has risen 34.29% since April 17, 2017 and is uptrending. It has outperformed by 22.74% the S&P500.

Orion Engineered Carbons, S.A. (NYSE:OEC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.